Genesis Genomics is a world leader in the development of molecular diagnostic tests for the early detection of cancer and other widespread diseases. Our Biomarker Discovery Platform, a high-throughput multi-application molecular screening technology, enables early detection and characterization of many types of cancer at the molecular level. This provides clinicians an opportunity for early screening as well as better prognostic indicators. Using breakthrough technology, our Biomarker Discovery Platform not only identifies significant, disease-associated markers, but also potential therapeutic targets.

Based on its encompassing core technology, Genesis Genomics has currently developed technologies, assays, services and molecular diagnostic tests for prostate cancer and UVR damage to skin. Work on early breast cancer detection is progressing rapidly.

This technology is also applicable to other forms of disease conditions. At Genesis Genomics, our focus is to develop new technologies that extend life, reduce treatment cost, and improve quality of life for cancer patients and other patients.

Genesis Genomics is proud of the fact that we have been named one of Canada's Top 10 Life Science Companies